Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Cosmos Health secures financing of up to $300 million to develop an ETH-backed treasury, with remaining proceeds for growth and general working capital
-
Cosmos Health delivered adjusted profitability in Q1 2025, with gross profit up 54% and cash burn down 95%, nearing breakeven.
-
Cosmos Health delivered adjusted profitability in Q1 2025, with gross profit up 54% and cash burn down 95%, nearing breakeven.
-
Cosmos Health lands follow-up order for 80K Sky Premium Life units in UAE after initial 130K sell-out, supporting 5-year goal of 3M+ units.
-
Cosmos Health is eligible for an additional 180 calendar day period to regain compliance with the Nasdaq’s minimum bid price requirement.
-
Greg Siokas has increased his stake in the Company by acquiring 1,466,764 common shares for $526,000.
-
FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses.
-
Cosmos Health continues upgrading its Cana facility and signs a contract with Pharmex to produce 300K bottles of the antiseptic drug AMBITASOL 1L.
-
Cosmos Health launches Sky Premium Life in Albania with Pharma Cell as distributor and secures an initial annual order valued at $300,000.
-
Taglich Brothers, Inc. announces that it has initiated coverage of Cosmos Health Inc. (NASDAQ: COSM).